What Makes Lineage Cell Therapeutics Inc. (AMEX: LCTX) One Of The Best Momentum Picks? – Stocks Register
Home  »  Finance   »  What Makes Lineage Cell Therapeutics Inc. (AMEX: L...

What Makes Lineage Cell Therapeutics Inc. (AMEX: LCTX) One Of The Best Momentum Picks?

Lineage Cell Therapeutics Inc. (AMEX:LCTX) shares, rose in value on Thursday, 06/10/21, with the stock price down by 0.00% to the previous day’s close as strong demand from buyers drove the stock to $2.81.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Actively observing the price movement in the last trading, the stock closed the session at $2.81, falling within a range of $2.77 and $2.84. Referring to stock’s 52-week performance, its high was $3.13, and the low was $0.73. On the whole, LCTX has fluctuated by 16.60% over the past month.

As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.04, which is expected to increase to -$0.03 for fiscal year -$0.16 and then to about -$0.21 by fiscal year 2022. Data indicates that the EPS growth is expected to be -14.30% in 2022, while the next year’s EPS growth is forecast to be -31.20%.

Analysts have estimated the company’s revenue for the quarter at $510k, with a low estimate of $400k and a high estimate of $700k. According to the average forecast, sales growth in current quarter could jump up 32.10%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $2.95 million, representing an increase of 61.60% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that LCTX’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.

7 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 1 analyst(s), 6 recommend it as a Buy and 0 called the LCTX stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of LCTX currently trading nearly 11.86% and 12.22% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 58.51, while the 7-day volatility ratio is showing 5.46% which for the 30-day chart, stands at 6.68%. Furthermore, Lineage Cell Therapeutics Inc. (LCTX)’s beta value is 1.86, and its average true range (ATR) is 0.19. The company’s stock has been forecasted to trade at an average price of $5.33 over the course of the next 52 weeks, with a low of $4.00 and a high of $7.00. Based on these price targets, the low is -42.35% off current price, whereas the price has to move -149.11% to reach the yearly target high. Additionally, analysts’ median price of $5.50 is likely to be welcomed by investors because it represents a decrease of -95.73% from the current levels.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



Data on historical trading for Lineage Cell Therapeutics Inc. (AMEX:LCTX) indicates that the trading volumes over the past 10 days have averaged 2.41 million and over the past 3 months, they’ve averaged 1.21 million. According to company’s latest data on outstanding shares, there are 158.72 million shares outstanding.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Nearly 3.50% of Lineage Cell Therapeutics Inc.’s shares belong to company insiders and institutional investors own 37.20% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 6.41 million shares as on May 27, 2021, resulting in a short ratio of 7.92. According to the data, the short interest in Lineage Cell Therapeutics Inc. (LCTX) stood at 3.95% of shares outstanding as of May 27, 2021; the number of short shares registered in Apr 29, 2021 reached 5.52 million. The stock has risen by 59.66% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LCTX stock heading into the next quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.